nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Ethinyl Estradiol—osteoporosis	0.0938	0.133	CbGbCtD
Linagliptin—CYP3A4—Calcitriol—osteoporosis	0.0872	0.124	CbGbCtD
Linagliptin—CYP3A4—Estropipate—osteoporosis	0.0872	0.124	CbGbCtD
Linagliptin—CYP3A4—Ergocalciferol—osteoporosis	0.0697	0.099	CbGbCtD
Linagliptin—ABCB1—Conjugated Estrogens—osteoporosis	0.0688	0.0978	CbGbCtD
Linagliptin—ABCB1—Estradiol—osteoporosis	0.0604	0.0859	CbGbCtD
Linagliptin—CYP3A4—Raloxifene—osteoporosis	0.0582	0.0827	CbGbCtD
Linagliptin—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0562	0.0798	CbGbCtD
Linagliptin—CYP3A4—Cholecalciferol—osteoporosis	0.0449	0.0638	CbGbCtD
Linagliptin—CYP3A4—Conjugated Estrogens—osteoporosis	0.0412	0.0586	CbGbCtD
Linagliptin—CYP3A4—Estradiol—osteoporosis	0.0362	0.0514	CbGbCtD
Linagliptin—Weight increased—Raloxifene—osteoporosis	0.00195	0.00657	CcSEcCtD
Linagliptin—Constipation—Calcium Acetate—osteoporosis	0.00189	0.00639	CcSEcCtD
Linagliptin—Infestation NOS—Ibandronate—osteoporosis	0.00189	0.00638	CcSEcCtD
Linagliptin—Infestation—Ibandronate—osteoporosis	0.00189	0.00638	CcSEcCtD
Linagliptin—Urinary tract infection—Raloxifene—osteoporosis	0.00185	0.00626	CcSEcCtD
Linagliptin—Urinary tract infection—Ibandronate—osteoporosis	0.00184	0.0062	CcSEcCtD
Linagliptin—Nasopharyngitis—Risedronate—osteoporosis	0.00181	0.0061	CcSEcCtD
Linagliptin—Urinary tract infection—Calcitriol—osteoporosis	0.0018	0.00607	CcSEcCtD
Linagliptin—Skin exfoliation—Estradiol—osteoporosis	0.00178	0.006	CcSEcCtD
Linagliptin—Pain in extremity—Zoledronate—osteoporosis	0.00175	0.00592	CcSEcCtD
Linagliptin—Nasopharyngitis—Pamidronate—osteoporosis	0.00172	0.0058	CcSEcCtD
Linagliptin—Pain in extremity—Conjugated Estrogens—osteoporosis	0.00169	0.0057	CcSEcCtD
Linagliptin—Constipation—Ergocalciferol—osteoporosis	0.00167	0.00564	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Ethinyl Estradiol—osteoporosis	0.00166	0.00562	CcSEcCtD
Linagliptin—Hypersensitivity—Calcium Acetate—osteoporosis	0.00163	0.0055	CcSEcCtD
Linagliptin—Weight increased—Ethinyl Estradiol—osteoporosis	0.00163	0.0055	CcSEcCtD
Linagliptin—Angioedema—Etidronic acid—osteoporosis	0.00163	0.00549	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Risedronate—osteoporosis	0.00162	0.00548	CcSEcCtD
Linagliptin—Immune system disorder—Estropipate—osteoporosis	0.0016	0.00539	CcSEcCtD
Linagliptin—Infestation—Ethinyl Estradiol—osteoporosis	0.0016	0.00539	CcSEcCtD
Linagliptin—Infestation NOS—Ethinyl Estradiol—osteoporosis	0.0016	0.00539	CcSEcCtD
Linagliptin—Mediastinal disorder—Estropipate—osteoporosis	0.00159	0.00538	CcSEcCtD
Linagliptin—Nasopharyngitis—Zoledronate—osteoporosis	0.00157	0.0053	CcSEcCtD
Linagliptin—Infestation NOS—Risedronate—osteoporosis	0.00156	0.00526	CcSEcCtD
Linagliptin—Infestation—Risedronate—osteoporosis	0.00156	0.00526	CcSEcCtD
Linagliptin—Urinary tract infection—Ethinyl Estradiol—osteoporosis	0.00155	0.00524	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Pamidronate—osteoporosis	0.00154	0.00521	CcSEcCtD
Linagliptin—Malnutrition—Estropipate—osteoporosis	0.00154	0.0052	CcSEcCtD
Linagliptin—Immune system disorder—Ibandronate—osteoporosis	0.00153	0.00517	CcSEcCtD
Linagliptin—Mediastinal disorder—Ibandronate—osteoporosis	0.00153	0.00516	CcSEcCtD
Linagliptin—Arthralgia—Etidronic acid—osteoporosis	0.00151	0.00511	CcSEcCtD
Linagliptin—Diarrhoea—Calcium Acetate—osteoporosis	0.00151	0.00511	CcSEcCtD
Linagliptin—Urinary tract infection—Risedronate—osteoporosis	0.00151	0.00511	CcSEcCtD
Linagliptin—Back pain—Estropipate—osteoporosis	0.00149	0.00503	CcSEcCtD
Linagliptin—Infestation—Pamidronate—osteoporosis	0.00148	0.005	CcSEcCtD
Linagliptin—Infestation NOS—Pamidronate—osteoporosis	0.00148	0.005	CcSEcCtD
Linagliptin—Malnutrition—Ibandronate—osteoporosis	0.00148	0.00498	CcSEcCtD
Linagliptin—Infection—Etidronic acid—osteoporosis	0.00144	0.00487	CcSEcCtD
Linagliptin—Urinary tract infection—Pamidronate—osteoporosis	0.00144	0.00486	CcSEcCtD
Linagliptin—Pancreatitis—Conjugated Estrogens—osteoporosis	0.00143	0.00483	CcSEcCtD
Linagliptin—Back pain—Ibandronate—osteoporosis	0.00143	0.00482	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Zoledronate—osteoporosis	0.00141	0.00476	CcSEcCtD
Linagliptin—Angioedema—Estropipate—osteoporosis	0.00141	0.00475	CcSEcCtD
Linagliptin—Angioedema—Alendronate—osteoporosis	0.00138	0.00468	CcSEcCtD
Linagliptin—Weight increased—Zoledronate—osteoporosis	0.00138	0.00466	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Conjugated Estrogens—osteoporosis	0.00136	0.00458	CcSEcCtD
Linagliptin—Pain in extremity—Estradiol—osteoporosis	0.00135	0.00456	CcSEcCtD
Linagliptin—Infestation NOS—Zoledronate—osteoporosis	0.00135	0.00456	CcSEcCtD
Linagliptin—Infestation—Zoledronate—osteoporosis	0.00135	0.00456	CcSEcCtD
Linagliptin—Angioedema—Ibandronate—osteoporosis	0.00135	0.00455	CcSEcCtD
Linagliptin—Cough—Estropipate—osteoporosis	0.00134	0.00453	CcSEcCtD
Linagliptin—Weight increased—Conjugated Estrogens—osteoporosis	0.00133	0.00449	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.00132	0.00447	CcSEcCtD
Linagliptin—Urinary tract infection—Zoledronate—osteoporosis	0.00131	0.00444	CcSEcCtD
Linagliptin—Arthralgia—Estropipate—osteoporosis	0.00131	0.00442	CcSEcCtD
Linagliptin—Myalgia—Estropipate—osteoporosis	0.00131	0.00442	CcSEcCtD
Linagliptin—Infestation NOS—Conjugated Estrogens—osteoporosis	0.0013	0.00439	CcSEcCtD
Linagliptin—Infestation—Conjugated Estrogens—osteoporosis	0.0013	0.00439	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.0013	0.00439	CcSEcCtD
Linagliptin—Cough—Raloxifene—osteoporosis	0.0013	0.00439	CcSEcCtD
Linagliptin—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00129	0.00437	CcSEcCtD
Linagliptin—Myalgia—Alendronate—osteoporosis	0.00129	0.00436	CcSEcCtD
Linagliptin—Arthralgia—Raloxifene—osteoporosis	0.00127	0.00429	CcSEcCtD
Linagliptin—Myalgia—Raloxifene—osteoporosis	0.00127	0.00429	CcSEcCtD
Linagliptin—Immune system disorder—Risedronate—osteoporosis	0.00126	0.00426	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00126	0.00426	CcSEcCtD
Linagliptin—Mediastinal disorder—Risedronate—osteoporosis	0.00126	0.00425	CcSEcCtD
Linagliptin—Arthralgia—Ibandronate—osteoporosis	0.00126	0.00424	CcSEcCtD
Linagliptin—Myalgia—Ibandronate—osteoporosis	0.00126	0.00424	CcSEcCtD
Linagliptin—Anaphylactic shock—Estropipate—osteoporosis	0.00126	0.00424	CcSEcCtD
Linagliptin—Infection—Estropipate—osteoporosis	0.00125	0.00421	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00125	0.00421	CcSEcCtD
Linagliptin—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00125	0.00421	CcSEcCtD
Linagliptin—Constipation—Etidronic acid—osteoporosis	0.00124	0.00419	CcSEcCtD
Linagliptin—Myalgia—Calcitriol—osteoporosis	0.00123	0.00415	CcSEcCtD
Linagliptin—Infection—Alendronate—osteoporosis	0.00123	0.00415	CcSEcCtD
Linagliptin—Skin disorder—Estropipate—osteoporosis	0.00122	0.00412	CcSEcCtD
Linagliptin—Malnutrition—Risedronate—osteoporosis	0.00122	0.00411	CcSEcCtD
Linagliptin—Infection—Raloxifene—osteoporosis	0.00121	0.00408	CcSEcCtD
Linagliptin—Nasopharyngitis—Estradiol—osteoporosis	0.00121	0.00408	CcSEcCtD
Linagliptin—Back pain—Ethinyl Estradiol—osteoporosis	0.00121	0.00407	CcSEcCtD
Linagliptin—Anaphylactic shock—Ibandronate—osteoporosis	0.0012	0.00407	CcSEcCtD
Linagliptin—Immune system disorder—Pamidronate—osteoporosis	0.0012	0.00405	CcSEcCtD
Linagliptin—Mediastinal disorder—Pamidronate—osteoporosis	0.0012	0.00404	CcSEcCtD
Linagliptin—Infection—Ibandronate—osteoporosis	0.0012	0.00404	CcSEcCtD
Linagliptin—Skin disorder—Raloxifene—osteoporosis	0.00118	0.00399	CcSEcCtD
Linagliptin—Anaphylactic shock—Calcitriol—osteoporosis	0.00118	0.00398	CcSEcCtD
Linagliptin—Back pain—Risedronate—osteoporosis	0.00118	0.00397	CcSEcCtD
Linagliptin—Skin disorder—Ibandronate—osteoporosis	0.00117	0.00395	CcSEcCtD
Linagliptin—Malnutrition—Pamidronate—osteoporosis	0.00116	0.0039	CcSEcCtD
Linagliptin—Urticaria—Etidronic acid—osteoporosis	0.00115	0.00389	CcSEcCtD
Linagliptin—Skin disorder—Calcitriol—osteoporosis	0.00115	0.00387	CcSEcCtD
Linagliptin—Pancreatitis—Estradiol—osteoporosis	0.00114	0.00387	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Estropipate—osteoporosis	0.00114	0.00386	CcSEcCtD
Linagliptin—Angioedema—Ethinyl Estradiol—osteoporosis	0.00114	0.00385	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00113	0.00381	CcSEcCtD
Linagliptin—Back pain—Pamidronate—osteoporosis	0.00112	0.00378	CcSEcCtD
Linagliptin—Angioedema—Risedronate—osteoporosis	0.00111	0.00375	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.00111	0.00374	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.0011	0.00371	CcSEcCtD
Linagliptin—Immune system disorder—Zoledronate—osteoporosis	0.0011	0.0037	CcSEcCtD
Linagliptin—Mediastinal disorder—Zoledronate—osteoporosis	0.00109	0.00369	CcSEcCtD
Linagliptin—Cough—Ethinyl Estradiol—osteoporosis	0.00109	0.00368	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Estradiol—osteoporosis	0.00109	0.00367	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Estropipate—osteoporosis	0.00108	0.00366	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00107	0.00363	CcSEcCtD
Linagliptin—Constipation—Estropipate—osteoporosis	0.00107	0.00363	CcSEcCtD
Linagliptin—Hypersensitivity—Etidronic acid—osteoporosis	0.00107	0.00361	CcSEcCtD
Linagliptin—Weight increased—Estradiol—osteoporosis	0.00106	0.00359	CcSEcCtD
Linagliptin—Cough—Risedronate—osteoporosis	0.00106	0.00358	CcSEcCtD
Linagliptin—Constipation—Alendronate—osteoporosis	0.00106	0.00357	CcSEcCtD
Linagliptin—Angioedema—Pamidronate—osteoporosis	0.00106	0.00357	CcSEcCtD
Linagliptin—Malnutrition—Zoledronate—osteoporosis	0.00106	0.00357	CcSEcCtD
Linagliptin—Immune system disorder—Conjugated Estrogens—osteoporosis	0.00105	0.00356	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00105	0.00356	CcSEcCtD
Linagliptin—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00105	0.00356	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00105	0.00355	CcSEcCtD
Linagliptin—Infestation—Estradiol—osteoporosis	0.00104	0.00352	CcSEcCtD
Linagliptin—Infestation NOS—Estradiol—osteoporosis	0.00104	0.00352	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00104	0.00351	CcSEcCtD
Linagliptin—Arthralgia—Risedronate—osteoporosis	0.00104	0.0035	CcSEcCtD
Linagliptin—Myalgia—Risedronate—osteoporosis	0.00104	0.0035	CcSEcCtD
Linagliptin—Constipation—Ibandronate—osteoporosis	0.00103	0.00348	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00103	0.00347	CcSEcCtD
Linagliptin—Back pain—Zoledronate—osteoporosis	0.00102	0.00345	CcSEcCtD
Linagliptin—Malnutrition—Conjugated Estrogens—osteoporosis	0.00102	0.00343	CcSEcCtD
Linagliptin—Urinary tract infection—Estradiol—osteoporosis	0.00101	0.00342	CcSEcCtD
Linagliptin—Infection—Ethinyl Estradiol—osteoporosis	0.00101	0.00342	CcSEcCtD
Linagliptin—Cough—Pamidronate—osteoporosis	0.00101	0.00341	CcSEcCtD
Linagliptin—Constipation—Calcitriol—osteoporosis	0.00101	0.0034	CcSEcCtD
Linagliptin—Urticaria—Estropipate—osteoporosis	0.000998	0.00337	CcSEcCtD
Linagliptin—Diarrhoea—Etidronic acid—osteoporosis	0.000993	0.00335	CcSEcCtD
Linagliptin—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000989	0.00334	CcSEcCtD
Linagliptin—Infection—Risedronate—osteoporosis	0.000986	0.00333	CcSEcCtD
Linagliptin—Arthralgia—Pamidronate—osteoporosis	0.000984	0.00332	CcSEcCtD
Linagliptin—Myalgia—Pamidronate—osteoporosis	0.000984	0.00332	CcSEcCtD
Linagliptin—Back pain—Conjugated Estrogens—osteoporosis	0.000983	0.00332	CcSEcCtD
Linagliptin—Urticaria—Alendronate—osteoporosis	0.000983	0.00332	CcSEcCtD
Linagliptin—Angioedema—Zoledronate—osteoporosis	0.000965	0.00326	CcSEcCtD
Linagliptin—Skin disorder—Risedronate—osteoporosis	0.000964	0.00326	CcSEcCtD
Linagliptin—Urticaria—Ibandronate—osteoporosis	0.000957	0.00323	CcSEcCtD
Linagliptin—Anaphylactic shock—Pamidronate—osteoporosis	0.000943	0.00319	CcSEcCtD
Linagliptin—Infection—Pamidronate—osteoporosis	0.000937	0.00317	CcSEcCtD
Linagliptin—Urticaria—Calcitriol—osteoporosis	0.000937	0.00316	CcSEcCtD
Linagliptin—Angioedema—Conjugated Estrogens—osteoporosis	0.000929	0.00314	CcSEcCtD
Linagliptin—Hypersensitivity—Estropipate—osteoporosis	0.000925	0.00312	CcSEcCtD
Linagliptin—Cough—Zoledronate—osteoporosis	0.000921	0.00311	CcSEcCtD
Linagliptin—Rash—Etidronic acid—osteoporosis	0.000915	0.00309	CcSEcCtD
Linagliptin—Dermatitis—Etidronic acid—osteoporosis	0.000914	0.00309	CcSEcCtD
Linagliptin—Hypersensitivity—Alendronate—osteoporosis	0.000911	0.00308	CcSEcCtD
Linagliptin—Headache—Etidronic acid—osteoporosis	0.000909	0.00307	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000904	0.00305	CcSEcCtD
Linagliptin—Arthralgia—Zoledronate—osteoporosis	0.000899	0.00304	CcSEcCtD
Linagliptin—Myalgia—Zoledronate—osteoporosis	0.000899	0.00304	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000893	0.00302	CcSEcCtD
Linagliptin—Hypersensitivity—Ibandronate—osteoporosis	0.000887	0.003	CcSEcCtD
Linagliptin—Cough—Conjugated Estrogens—osteoporosis	0.000887	0.003	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000879	0.00297	CcSEcCtD
Linagliptin—Constipation—Ethinyl Estradiol—osteoporosis	0.00087	0.00294	CcSEcCtD
Linagliptin—Hypersensitivity—Calcitriol—osteoporosis	0.000869	0.00293	CcSEcCtD
Linagliptin—Arthralgia—Conjugated Estrogens—osteoporosis	0.000866	0.00292	CcSEcCtD
Linagliptin—Myalgia—Conjugated Estrogens—osteoporosis	0.000866	0.00292	CcSEcCtD
Linagliptin—Anaphylactic shock—Zoledronate—osteoporosis	0.000862	0.00291	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00086	0.0029	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00086	0.0029	CcSEcCtD
Linagliptin—Diarrhoea—Estropipate—osteoporosis	0.000859	0.0029	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Risedronate—osteoporosis	0.000857	0.00289	CcSEcCtD
Linagliptin—Infection—Zoledronate—osteoporosis	0.000856	0.00289	CcSEcCtD
Linagliptin—Constipation—Risedronate—osteoporosis	0.000849	0.00287	CcSEcCtD
Linagliptin—Diarrhoea—Alendronate—osteoporosis	0.000846	0.00286	CcSEcCtD
Linagliptin—Immune system disorder—Estradiol—osteoporosis	0.000844	0.00285	CcSEcCtD
Linagliptin—Mediastinal disorder—Estradiol—osteoporosis	0.000842	0.00285	CcSEcCtD
Linagliptin—Skin disorder—Zoledronate—osteoporosis	0.000837	0.00283	CcSEcCtD
Linagliptin—Diarrhoea—Raloxifene—osteoporosis	0.000832	0.00281	CcSEcCtD
Linagliptin—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.00083	0.0028	CcSEcCtD
Linagliptin—Infection—Conjugated Estrogens—osteoporosis	0.000824	0.00278	CcSEcCtD
Linagliptin—Diarrhoea—Ibandronate—osteoporosis	0.000824	0.00278	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000815	0.00275	CcSEcCtD
Linagliptin—Malnutrition—Estradiol—osteoporosis	0.000814	0.00275	CcSEcCtD
Linagliptin—Urticaria—Ethinyl Estradiol—osteoporosis	0.000809	0.00273	CcSEcCtD
Linagliptin—Constipation—Pamidronate—osteoporosis	0.000807	0.00272	CcSEcCtD
Linagliptin—Diarrhoea—Calcitriol—osteoporosis	0.000807	0.00272	CcSEcCtD
Linagliptin—Skin disorder—Conjugated Estrogens—osteoporosis	0.000806	0.00272	CcSEcCtD
Linagliptin—Rash—Estropipate—osteoporosis	0.000792	0.00267	CcSEcCtD
Linagliptin—Dermatitis—Estropipate—osteoporosis	0.000791	0.00267	CcSEcCtD
Linagliptin—Urticaria—Risedronate—osteoporosis	0.000788	0.00266	CcSEcCtD
Linagliptin—Back pain—Estradiol—osteoporosis	0.000787	0.00266	CcSEcCtD
Linagliptin—Headache—Estropipate—osteoporosis	0.000787	0.00266	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000785	0.00265	CcSEcCtD
Linagliptin—Rash—Alendronate—osteoporosis	0.00078	0.00263	CcSEcCtD
Linagliptin—Dermatitis—Alendronate—osteoporosis	0.000779	0.00263	CcSEcCtD
Linagliptin—Headache—Alendronate—osteoporosis	0.000775	0.00262	CcSEcCtD
Linagliptin—Rash—Raloxifene—osteoporosis	0.000767	0.00259	CcSEcCtD
Linagliptin—Dermatitis—Raloxifene—osteoporosis	0.000766	0.00259	CcSEcCtD
Linagliptin—Headache—Raloxifene—osteoporosis	0.000762	0.00257	CcSEcCtD
Linagliptin—Rash—Ibandronate—osteoporosis	0.000759	0.00256	CcSEcCtD
Linagliptin—Dermatitis—Ibandronate—osteoporosis	0.000759	0.00256	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000756	0.00255	CcSEcCtD
Linagliptin—Headache—Ibandronate—osteoporosis	0.000754	0.00255	CcSEcCtD
Linagliptin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00075	0.00253	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000744	0.00251	CcSEcCtD
Linagliptin—Angioedema—Estradiol—osteoporosis	0.000744	0.00251	CcSEcCtD
Linagliptin—Rash—Calcitriol—osteoporosis	0.000743	0.00251	CcSEcCtD
Linagliptin—Dermatitis—Calcitriol—osteoporosis	0.000743	0.00251	CcSEcCtD
Linagliptin—Headache—Calcitriol—osteoporosis	0.000739	0.00249	CcSEcCtD
Linagliptin—Constipation—Zoledronate—osteoporosis	0.000737	0.00249	CcSEcCtD
Linagliptin—Hypersensitivity—Risedronate—osteoporosis	0.000731	0.00247	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000716	0.00242	CcSEcCtD
Linagliptin—Cough—Estradiol—osteoporosis	0.00071	0.0024	CcSEcCtD
Linagliptin—Constipation—Conjugated Estrogens—osteoporosis	0.00071	0.0024	CcSEcCtD
Linagliptin—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000696	0.00235	CcSEcCtD
Linagliptin—Hypersensitivity—Pamidronate—osteoporosis	0.000695	0.00235	CcSEcCtD
Linagliptin—Myalgia—Estradiol—osteoporosis	0.000693	0.00234	CcSEcCtD
Linagliptin—Arthralgia—Estradiol—osteoporosis	0.000693	0.00234	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000688	0.00232	CcSEcCtD
Linagliptin—Urticaria—Zoledronate—osteoporosis	0.000685	0.00231	CcSEcCtD
Linagliptin—Diarrhoea—Risedronate—osteoporosis	0.000679	0.00229	CcSEcCtD
Linagliptin—Anaphylactic shock—Estradiol—osteoporosis	0.000664	0.00224	CcSEcCtD
Linagliptin—Infection—Estradiol—osteoporosis	0.00066	0.00223	CcSEcCtD
Linagliptin—Urticaria—Conjugated Estrogens—osteoporosis	0.000659	0.00223	CcSEcCtD
Linagliptin—Diarrhoea—Pamidronate—osteoporosis	0.000646	0.00218	CcSEcCtD
Linagliptin—Skin disorder—Estradiol—osteoporosis	0.000645	0.00218	CcSEcCtD
Linagliptin—Rash—Ethinyl Estradiol—osteoporosis	0.000642	0.00217	CcSEcCtD
Linagliptin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000641	0.00217	CcSEcCtD
Linagliptin—Headache—Ethinyl Estradiol—osteoporosis	0.000638	0.00215	CcSEcCtD
Linagliptin—Hypersensitivity—Zoledronate—osteoporosis	0.000635	0.00214	CcSEcCtD
Linagliptin—Rash—Risedronate—osteoporosis	0.000626	0.00211	CcSEcCtD
Linagliptin—Dermatitis—Risedronate—osteoporosis	0.000625	0.00211	CcSEcCtD
Linagliptin—Headache—Risedronate—osteoporosis	0.000622	0.0021	CcSEcCtD
Linagliptin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000611	0.00206	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000605	0.00204	CcSEcCtD
Linagliptin—Rash—Pamidronate—osteoporosis	0.000595	0.00201	CcSEcCtD
Linagliptin—Dermatitis—Pamidronate—osteoporosis	0.000594	0.00201	CcSEcCtD
Linagliptin—Headache—Pamidronate—osteoporosis	0.000591	0.002	CcSEcCtD
Linagliptin—Diarrhoea—Zoledronate—osteoporosis	0.00059	0.00199	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Estradiol—osteoporosis	0.000573	0.00194	CcSEcCtD
Linagliptin—Constipation—Estradiol—osteoporosis	0.000568	0.00192	CcSEcCtD
Linagliptin—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000568	0.00192	CcSEcCtD
Linagliptin—Rash—Zoledronate—osteoporosis	0.000543	0.00184	CcSEcCtD
Linagliptin—Dermatitis—Zoledronate—osteoporosis	0.000543	0.00183	CcSEcCtD
Linagliptin—Headache—Zoledronate—osteoporosis	0.00054	0.00182	CcSEcCtD
Linagliptin—Urticaria—Estradiol—osteoporosis	0.000528	0.00178	CcSEcCtD
Linagliptin—Rash—Conjugated Estrogens—osteoporosis	0.000523	0.00177	CcSEcCtD
Linagliptin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000523	0.00177	CcSEcCtD
Linagliptin—Headache—Conjugated Estrogens—osteoporosis	0.00052	0.00176	CcSEcCtD
Linagliptin—Hypersensitivity—Estradiol—osteoporosis	0.000489	0.00165	CcSEcCtD
Linagliptin—Diarrhoea—Estradiol—osteoporosis	0.000454	0.00153	CcSEcCtD
Linagliptin—Rash—Estradiol—osteoporosis	0.000419	0.00141	CcSEcCtD
Linagliptin—Dermatitis—Estradiol—osteoporosis	0.000418	0.00141	CcSEcCtD
Linagliptin—Headache—Estradiol—osteoporosis	0.000416	0.00141	CcSEcCtD
